Chen Yuan1, Clary B Clish1, Chen Wu1, Jared R Mayers1, Peter Kraft1, Mary K Townsend1, Mingfeng Zhang1, Shelley S Tworoger1, Ying Bao1, Zhi Rong Qian1, Douglas A Rubinson1, Kimmie Ng1, Edward L Giovannucci1, Shuji Ogino1, Meir J Stampfer1, John Michael Gaziano1, Jing Ma1, Howard D Sesso1, Garnet L Anderson1, Barbara B Cochrane1, JoAnn E Manson1, Margaret E Torrence1, Alec C Kimmelman1, Laufey T Amundadottir1, Matthew G Vander Heiden1, Charles S Fuchs1, Brian M Wolpin2. 1. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (CY, ZRQ, DAR, KN, SO, MGVH, CSF, BMW); Broad Institute of MIT and Harvard University, Cambridge, MA (CBC, MGVH); Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China (CW); Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA (JRM, MET, MGVH); Department of Epidemiology (PK, SST, ELG, SO, MJS, JM, HDS, JEM), Department of Biostatistics (PK), and Department of Nutrition (ELG, MJS), Harvard School of Public Health, Boston, MA; Department of Pathology (SO), and Channing Division of Network Medicine (MKT, SST, YB, ELG, MJS, JM, JEM, CSF) and Division of Preventive Medicine (JMG, HDS, JEM), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (MZ, LTA); Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA (JMG); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA); University of Washington School of Nursing, Seattle, WA (BBC); Division of Genomic Stability and DNA repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA (ACK). 2. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (CY, ZRQ, DAR, KN, SO, MGVH, CSF, BMW); Broad Institute of MIT and Harvard University, Cambridge, MA (CBC, MGVH); Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China (CW); Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA (JRM, MET, MGVH); Department of Epidemiology (PK, SST, ELG, SO, MJS, JM, HDS, JEM), Department of Biostatistics (PK), and Department of Nutrition (ELG, MJS), Harvard School of Public Health, Boston, MA; Department of Pathology (SO), and Channing Division of Network Medicine (MKT, SST, YB, ELG, MJS, JM, JEM, CSF) and Division of Preventive Medicine (JMG, HDS, JEM), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (MZ, LTA); Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA (JMG); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA); University of Washington School of Nursing, Seattle, WA (BBC); Division of Genomic Stability and DNA repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA (ACK). bwolpin@partners.org.
Abstract
BACKGROUND: Pancreatic tumors cause changes in whole-body metabolism, but whether prediagnostic circulating metabolites predict survival is unknown. METHODS: We measured 82 metabolites by liquid chromatography-mass spectrometry in prediagnostic plasma from 484 pancreatic cancer case patients enrolled in four prospective cohort studies. Association of metabolites with survival was evaluated using Cox proportional hazards models adjusted for age, cohort, race/ethnicity, cancer stage, fasting time, and diagnosis year. After multiple-hypothesis testing correction, a P value of .0006 or less (.05/82) was considered statistically significant. Based on the results, we evaluated 33 tagging single-nucleotide polymorphisms (SNPs) in the ACO1 gene, requiring a P value of less than .002 (.05/33) for statistical significance. All statistical tests were two-sided. RESULTS: Two metabolites in the tricarboxylic acid (TCA) cycle--isocitrate and aconitate--were statistically significantly associated with survival. Participants in the highest vs lowest quintile had hazard ratios (HRs) for death of 1.89 (95% confidence interval [CI] = 1.06 to 3.35, Ptrend < .001) for isocitrate and 2.54 (95% CI = 1.42 to 4.54, Ptrend < .001) for aconitate. Isocitrate is interconverted with citrate via the intermediate aconitate in a reaction catalyzed by the enzyme aconitase 1 (ACO1). Therefore, we investigated the citrate to aconitate plus isocitrate ratio and SNPs in the ACO1 gene. The ratio was strongly associated with survival (P trend < .001) as was the SNP rs7874815 in the ACO1 gene (hazard ratio for death per minor allele = 1.37, 95% CI = 1.16 to 1.61, P < .001). Patients had an approximately three-fold hazard for death when possessing one or more minor alleles at rs7874851 and high aconitate or isocitrate. CONCLUSIONS: Prediagnostic circulating levels of TCA cycle intermediates and inherited ACO1 genotypes were associated with survival among patients with pancreatic cancer.
BACKGROUND:Pancreatic tumors cause changes in whole-body metabolism, but whether prediagnostic circulating metabolites predict survival is unknown. METHODS: We measured 82 metabolites by liquid chromatography-mass spectrometry in prediagnostic plasma from 484 pancreatic cancer case patients enrolled in four prospective cohort studies. Association of metabolites with survival was evaluated using Cox proportional hazards models adjusted for age, cohort, race/ethnicity, cancer stage, fasting time, and diagnosis year. After multiple-hypothesis testing correction, a P value of .0006 or less (.05/82) was considered statistically significant. Based on the results, we evaluated 33 tagging single-nucleotide polymorphisms (SNPs) in the ACO1 gene, requiring a P value of less than .002 (.05/33) for statistical significance. All statistical tests were two-sided. RESULTS: Two metabolites in the tricarboxylic acid (TCA) cycle--isocitrate and aconitate--were statistically significantly associated with survival. Participants in the highest vs lowest quintile had hazard ratios (HRs) for death of 1.89 (95% confidence interval [CI] = 1.06 to 3.35, Ptrend < .001) for isocitrate and 2.54 (95% CI = 1.42 to 4.54, Ptrend < .001) for aconitate. Isocitrate is interconverted with citrate via the intermediate aconitate in a reaction catalyzed by the enzyme aconitase 1 (ACO1). Therefore, we investigated the citrate to aconitate plus isocitrate ratio and SNPs in the ACO1 gene. The ratio was strongly associated with survival (P trend < .001) as was the SNP rs7874815 in the ACO1 gene (hazard ratio for death per minor allele = 1.37, 95% CI = 1.16 to 1.61, P < .001). Patients had an approximately three-fold hazard for death when possessing one or more minor alleles at rs7874851 and high aconitate or isocitrate. CONCLUSIONS: Prediagnostic circulating levels of TCA cycle intermediates and inherited ACO1 genotypes were associated with survival among patients with pancreatic cancer.
Authors: Brian M Wolpin; Kimmie Ng; Ying Bao; Peter Kraft; Meir J Stampfer; Dominique S Michaud; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Barbara B Cochrane; Jean Wactawski-Wende; Rowan T Chlebowski; Walter C Willett; JoAnn E Manson; Edward L Giovannucci; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-15 Impact factor: 4.254
Authors: Jurre J Kamphorst; Michel Nofal; Cosimo Commisso; Sean R Hackett; Wenyun Lu; Elda Grabocka; Matthew G Vander Heiden; George Miller; Jeffrey A Drebin; Dafna Bar-Sagi; Craig B Thompson; Joshua D Rabinowitz Journal: Cancer Res Date: 2015-02-01 Impact factor: 12.701
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: W A Ghali; H Quan; R Brant; G van Melle; C M Norris; P D Faris; P D Galbraith; M L Knudtson Journal: JAMA Date: 2001-09-26 Impact factor: 56.272
Authors: Chen Yuan; Ying Bao; Chen Wu; Peter Kraft; Shuji Ogino; Kimmie Ng; Zhi Rong Qian; Douglas A Rubinson; Meir J Stampfer; Edward L Giovannucci; Brian M Wolpin Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544
Authors: Jared R Mayers; Chen Wu; Clary B Clish; Peter Kraft; Margaret E Torrence; Brian P Fiske; Chen Yuan; Ying Bao; Mary K Townsend; Shelley S Tworoger; Shawn M Davidson; Thales Papagiannakopoulos; Annan Yang; Talya L Dayton; Shuji Ogino; Meir J Stampfer; Edward L Giovannucci; Zhi Rong Qian; Douglas A Rubinson; Jing Ma; Howard D Sesso; John Michael Gaziano; Barbara B Cochrane; Simin Liu; Jean Wactawski-Wende; JoAnn E Manson; Michael N Pollak; Alec C Kimmelman; Amanda Souza; Kerry Pierce; Thomas J Wang; Robert E Gerszten; Charles S Fuchs; Matthew G Vander Heiden; Brian M Wolpin Journal: Nat Med Date: 2014-09-28 Impact factor: 53.440
Authors: Elin Grundberg; Kerrin S Small; Åsa K Hedman; Alexandra C Nica; Alfonso Buil; Sarah Keildson; Jordana T Bell; Tsun-Po Yang; Eshwar Meduri; Amy Barrett; James Nisbett; Magdalena Sekowska; Alicja Wilk; So-Youn Shin; Daniel Glass; Mary Travers; Josine L Min; Sue Ring; Karen Ho; Gudmar Thorleifsson; Augustine Kong; Unnur Thorsteindottir; Chrysanthi Ainali; Antigone S Dimas; Neelam Hassanali; Catherine Ingle; David Knowles; Maria Krestyaninova; Christopher E Lowe; Paola Di Meglio; Stephen B Montgomery; Leopold Parts; Simon Potter; Gabriela Surdulescu; Loukia Tsaprouni; Sophia Tsoka; Veronique Bataille; Richard Durbin; Frank O Nestle; Stephen O'Rahilly; Nicole Soranzo; Cecilia M Lindgren; Krina T Zondervan; Kourosh R Ahmadi; Eric E Schadt; Kari Stefansson; George Davey Smith; Mark I McCarthy; Panos Deloukas; Emmanouil T Dermitzakis; Tim D Spector Journal: Nat Genet Date: 2012-09-02 Impact factor: 38.330
Authors: Tsuyoshi Hamada; Chen Yuan; Shuji Ogino; Brian M Wolpin; Ying Bao; Mingfeng Zhang; Natalia Khalaf; Ana Babic; Vicente Morales-Oyarvide; Barbara B Cochrane; J Michael Gaziano; Edward L Giovannucci; Peter Kraft; JoAnn E Manson; Kimmie Ng; Jonathan A Nowak; Thomas E Rohan; Howard D Sesso; Meir J Stampfer; Laufey T Amundadottir; Charles S Fuchs; Immaculata De Vivo Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-19 Impact factor: 4.254
Authors: Katherine S Yang; Hyungsoon Im; Seonki Hong; Ilaria Pergolini; Andres Fernandez Del Castillo; Rui Wang; Susan Clardy; Chen-Han Huang; Craig Pille; Soldano Ferrone; Robert Yang; Cesar M Castro; Hakho Lee; Carlos Fernandez Del Castillo; Ralph Weissleder Journal: Sci Transl Med Date: 2017-05-24 Impact factor: 17.956
Authors: Mary K Townsend; Hugues Aschard; Immaculata De Vivo; Karin B Michels; Peter Kraft Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Brenda M Birmann; Mollie E Barnard; Kimberly A Bertrand; Ying Bao; Marta Crous-Bou; Brian M Wolpin; Immaculata De Vivo; Shelley S Tworoger Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Julia Mayerle; Holger Kalthoff; Regina Reszka; Beate Kamlage; Erik Peter; Bodo Schniewind; Sandra González Maldonado; Christian Pilarsky; Claus-Dieter Heidecke; Philipp Schatz; Marius Distler; Jonas A Scheiber; Ujjwal M Mahajan; F Ulrich Weiss; Robert Grützmann; Markus M Lerch Journal: Gut Date: 2017-01-20 Impact factor: 23.059
Authors: Kerry L Ivey; Eric B Rimm; Peter Kraft; Clary B Clish; Aedin Cassidy; Jonathan Hodgson; Kevin Croft; Brian Wolpin; Liming Liang Journal: J Nutr Sci Date: 2017-07-14